BioPharma Resources

Company

Vanda Pharms INC

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

6

6 still marketed

Novel approvals

5

Approvals since 2021

4

Originals and new uses

Phase 3 trials

0

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Bysanti approved NovelFeb 20, 2026
  • Nereus approved NovelDec 30, 2025
  • Fanapt new use Apr 2, 2024
  • Ponvory approved NovelMar 18, 2021
  • Hetlioz Lq approved Priority reviewOrphanDec 1, 2020
  • Hetlioz new use Priority reviewOrphanDec 1, 2020
  • Fanapt new use May 26, 2016
  • Hetlioz approved NovelPriority reviewOrphanJan 31, 2014
  • Fanapt approved NovelMay 6, 2009

Drugs in development (0)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

No investigational drugs in Phase 2 or 3 trials under this sponsor name.

Recruiting Phase 3 trials

Largest first.

No recruiting Phase 3 trials under this sponsor name.

Marketed drugs (6)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.